Screener Summaries Updates Institutions Sign In More Updates › Other Events › REPL Other Events · Jun 26, 2026
Replimune Group, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review the… REPL Replimune Group, Inc.
Replimune Group, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for treating advanced melanoma. Replimune Group, Inc. is a biotechnology company focused on developing oncolytic virotherapy for-the-treatment of cancer.
More from Replimune Group, Inc. Replimune reports $57.1M Q2 loss as TUDRIQEV launches for advanced melanoma Oct 28, 2026 Replimune Group, Inc. held its annual meeting of stockholders on September 15, 2026, where shareholders approved an… Sep 16, 2026 Replimune Group, Inc. announced the FDA accelerated approval of TUDRIQEV (vusolimogene oderparepvec-wtpg) in… Aug 14, 2026 Replimune Group, Inc. entered into an underwriting agreement to issue and sell 9,701,490 shares of common stock and… Aug 10, 2026 Replimune Group, Inc. priced an underwritten public offering of 9,701,490 shares of common stock at $12.06 per share… Aug 10, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
